Davidson Kempner Capital Management LP Acquires New Shares in Tempus AI, Inc. (NASDAQ:TEM)

Davidson Kempner Capital Management LP bought a new position in Tempus AI, Inc. (NASDAQ:TEM) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $2,271,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Lingotto Investment Management LLP bought a new stake in Tempus AI during the 2nd quarter worth approximately $32,685,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Tempus AI in the second quarter worth $28,246,000. WINTON GROUP Ltd acquired a new stake in Tempus AI in the second quarter valued at $634,000. Allen Operations LLC acquired a new stake in Tempus AI in the second quarter valued at $3,831,000. Finally, Revolution Growth Management Company Inc. bought a new position in Tempus AI during the 2nd quarter worth $128,133,000.

Tempus AI Trading Up 8.7 %

Shares of NASDAQ TEM opened at $54.43 on Monday. The firm’s 50-day moving average is $48.37. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $77.00.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($6.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.41) by ($2.36). The company had revenue of $165.97 million during the quarter, compared to analyst estimates of $159.10 million. Equities analysts anticipate that Tempus AI, Inc. will post -6.51 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on TEM. Morgan Stanley initiated coverage on Tempus AI in a research report on Tuesday, July 9th. They issued an “overweight” rating and a $44.00 price target on the stock. TD Cowen started coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They set a “buy” rating and a $50.00 target price for the company. JPMorgan Chase & Co. raised their price target on shares of Tempus AI from $42.00 to $47.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $47.00 price objective on shares of Tempus AI in a research note on Wednesday, August 7th. Finally, Stifel Nicolaus began coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They set a “buy” rating and a $45.00 price objective for the company. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $45.56.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.